SEC Filing Analysis: IRADIMED CORP (IRMD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The CEO, President, and Chairman of IRADIMED CORP executed a minor, pre-planned sale of common stock totaling approximately $388,000.
• Market Impact: The transaction is unlikely to have a material impact on the stock price due to its small size relative to the company's market cap and the insider's vast holdings, and because it was executed under a Rule 10b5-1 plan.

Company Information

Field	Value
Company	IRADIMED CORP
Ticker Symbol	IRMD
CIK	0001325618
Industry	Surgical & Medical Instruments & Apparatus

Insider Information

Field	Value
Name	Susi Roger E.
CIK	0001613801
Title/Position	CEO, PRESIDENT, CHAIRMAN
Relationship	Director, Officer, 10% Owner

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-27
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	5,000
Price Per Share	$77.68 (Weighted Average)
Total Value	$388,418.68
Shares Owned After	4,552,950
Ownership Type	Indirect

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$388,418.68
% of Market Cap	0.039%
Shares Transacted	5,000
% of Shares Outstanding	0.039%
Post-Transaction Ownership	4,552,950 shares (35.8% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a $1.00 billion market capitalization, this transaction of ~$388k is negligible, representing less than 0.04% of the company's value.
• Ownership Concentration: The insider, Roger Susi, remains the largest shareholder by a significant margin. Even after this sale, his indirect holdings constitute approximately 35.8% of all shares outstanding, indicating his interests are still heavily aligned with the company's performance.
• Transaction Significance: The sale represents a tiny fraction of both the company's total shares (0.039%) and the insider's personal holdings. The sale of 5,000 shares is less than 0.11% of the insider's total position. This is considered routine portfolio management, not a significant change in conviction.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is too small to be considered material. Furthermore, its execution under a Rule 10b5-1 trading plan, adopted in June 2025, signals that the sale was pre-scheduled and not based on any immediate, non-public information.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is unlikely to cause a noticeable spike in trading volume.
• Sentiment Indicator: Neutral. The market generally discounts pre-planned sales by key insiders, especially when they represent a minuscule portion of their total holdings.

Investment Insights

Positive Market Indicators

• The insider maintains an exceptionally large ownership stake (~35.8%), demonstrating significant long-term alignment with shareholder interests.

Risk Factors

• No new risk factors are indicated by this filing. The transaction is routine.

Key Takeaways

1. Minor Transaction: The sale of $388k in stock is immaterial for a billion-dollar company and for an insider holding hundreds of millions of dollars in equity.
2. Pre-Planned Sale: The transaction was executed under a Rule 10b5-1 plan, which significantly diminishes its value as a real-time indicator of insider sentiment.
3. Dominant Ownership Unchanged: The CEO's position as the controlling shareholder is unaffected, and his financial interests remain deeply tied to the company's success.

Additional Context

Transaction Notes

• Special Circumstances: As per footnote F1, all sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025. The shares are held indirectly through various trusts.
• Market Environment: The transaction is a planned disposition and not necessarily a reaction to current market conditions.